Jefferies on Rocket Pharmaceuticals (RCKT): 'We expect significant stock weakness'
Tweet Send to a Friend
Jefferies analyst Andrew Tsai reiterated a Buy rating and $29.00 price target on Rocket Pharmaceuticals (NASDAQ: RCKT).The analyst comments "We ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
